GI Pancreatic - Metastatic

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#15588 Serial Measurements of Molecular and Architectural Responses to Therapy
- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic)

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB#23316 A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Pancreatic Adenocarcinoma
- IRB# 23124 A Phase I/II Randomized Study of AVB-S6500 plus Nab-Paclitaxel and Gemcitabine in Patients with Locally Advanced, Recurrent, or Metastatic Pancreatic Adenocarcinoma
- IRB# 22141 A Phase I, Open-Label, Dose Finding Study of Calaspargase Pegol-Mnkl in Combination with Cobimetinib in Locally Advanced or Metastatic Pancreatic Adenocarcinoma (Morpheus-Pancreatic Cancer)

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

- IRB# 17094 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Cross-Disease Trials:

- IRB# 20679 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment

KEY
- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
GI Pancreatic - Metastatic

Localized

- NeoAdjuvant
  - IRB #19211: A Feasibility Study to Assess a Window of Opportunity Strategy for Targeted PARP or MEK Inhibition in Patients with Pancreatic Ductal Adenocarcinoma

- Adjuvant
  - IRB #21614: NeoOptimize: An Open-Label, Phase II Trial To Assess The Efficacy Of Adaptive Switching Of mFolfirinox Or Gemcitabine/Nab-Paclitaxel As A NeoAdjuvant Strategy For Patients With Resectable And Borderline Resectable Pancreatic Cancer.
  - IRB #24549: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
  - IRB #17751: Trans(Intra)-arterial Gemcitabine vs. Continuation of IV Gemcitabine and Nab-Paclitaxel following Radiotherapy for Locally Advanced Pancreatic Cancer

KEY
- Open to Enrollment
- In Development
- Enrollment on Hold

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result
Quality Improvement Trials:

IRB # 22619: A Phase II Trial of Preoperative Endoscopic Botulinum Toxin Injection in the Prevention of Postoperative Pancreatic Fistula following Distal Pancreatectomy

IRB# 22413 Polyglycolic Acid Mesh to Prevent Pancreatic Fistula After Distal Pancreatectomy: A Multi-Center Efficacy Trial

https://apps.ohsu.edu/research/study-participation-opportunities-system/knight.php#result